Maria Xatzipsalti

Maria Xatzipsalti

Auto-generated profile, based on publicly available information

Maria Xatzipsalti

Diabetes center, 1(st) Pediatric Department, Children's Hospital , P&A Kyriakou, Athens, Greece

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2019 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
MXMaria Xatzipsalti
Maria Xatzipsalti
AVAntonis Voutetakis
Antonis Voutetakis
LSLela Stamoyannou
Lela Stamoyannou
GCGeorge P. Chrousos
George P. Chrousos
CKChristina Kanaka-Gantenbein
Christina Kanaka-Gantenbein
The ontogenesis and development of the pituitary gland is a highly complex process that depends on a cascade of transcription factors and signaling molecules. Spontaneous mutations and transgenic murine models have demonstrated a role for many of these factors, including HESX1, PROP1, PIT1, LHX3, LHX4, SOX2, SOX3, OTX2, PAX6, FGFR1, SHH, GLI2, and FGF8 in the etiology of congenital hypopituitarism. Genetic mutations in any of these factors can lead to congenital hypopituitarism, which is characterized by the deficiency in one or more pituitary hormones. The phenotype can be highly variable, consisting of isolated hypopituitarism or more complex disorders. The same phenotype can be attributed to different gene mutations; while a given gene mutation can induce different phenotypes. This review highlights the genetic variations that lead to congenital hypopituitarism and their associated defects. The overall incidence of mutations in known transcription factors in patients with hypopituitarism is low; therefore many gene mutations or even gene- epigenetic interactions have to be unraveled in the future to explain the vast majority of still unclear cases of congenital hypopituitarism.

29 May 2023 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
MXMaria Xatzipsalti
Maria Xatzipsalti
EBEvangelos Bourousis
Evangelos Bourousis
MNMaria Nikita
Maria Nikita
DRDimitra Rontogianni
Dimitra Rontogianni
MGMyrsini. G. Gkeli
Myrsini. G. Gkeli
AVAndriani Vazeou
Andriani Vazeou
Primary thyroid lymphoma (PTL) is a rare thyroid gland cancer, with diffuse large B-cell lymphomas (DLBCL) being extremely rare in children and adolescents. Thus, optimal therapy is debatable. We describe a rare case of thyroid DLBCL in an adolescent girl with a history of Hashimoto thyroiditis (HT), the difficulty in diagnosis and the outcome of treatment. A 12-year-old girl with a nine-year history of HT was admitted with a right-sided painless progressive swelling of the neck. Physical examination and imaging including ultrasound (US), computed tomography (CT) and positron emission tomography/CT revealed an enlarged thyroid gland with right side lymphadenopathy and no metastasis. Two fine needle aspirations were done showing suspected lymphoblastic lesions for non-Hodgkin lymphoma without precise diagnosis. US guided core needle biopsy was finally performed confirming the diagnosis of DLBCL. She was treated according to LMB 96-group B protocol with no surgical removal of thyroid. The patient responded very well to treatment and 14 months later there is no evidence of relapse or metastases. PTL is an extremely rare cause of thyroid malignancy in children. However, it should be considered in the differential diagnosis of a thyroid mass in adolescents presenting with a rapidly enlarging neck mass and a history of HT. It is a treatable condition with a good prognosis, even in aggressive histological subtypes, with no need for thyroidectomy.

21 October 2021 in Hormones
Verified
Journal Article
Closed access
PDF file
MXMaria Xatzipsalti
Maria Xatzipsalti
HAHlias Alvertis
Hlias Alvertis
GKGiannoula Kourousi
Giannoula Kourousi
KPKonstantina Patouni
Konstantina Patouni
SKSotiris Konstantakopoulos
Sotiris Konstantakopoulos
AVAndriani Vazeou
Andriani Vazeou

3 October 2021 in Diabetology International
Verified
Journal Article
Closed access
PDF file
MXMaria Xatzipsalti
Maria Xatzipsalti
HAHlias Alvertis
Hlias Alvertis
AVAndriani Vazeou
Andriani Vazeou

8 April 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
SSSebastian Seget
Sebastian Seget
EREwa Rusak
Ewa Rusak
JPJulie Pelicand
Julie Pelicand
MFMarylin Fry
Marylin Fry
NSNicole Sheanon
Nicole Sheanon
EHEva Hauser
Eva Hauser
Automated insulin delivery (AID) systems are increasingly used in type 1 diabetes (T1D) management, yet large-scale real-world evidence in pediatric populations remains limited. This study assessed the impact of AID therapy on glycemic outcomes in children and adolescents with T1D using data from the international SWEET registry. We performed an observational comparative study using two treatment periods (12 months before and after AID initiation). Data were obtained from the SWEET database, with 53 centers across 29 countries contributing eligible cases. Participants were children and adolescents (≤18 years) with T1D who initiated AID therapy between 2014 and 2022. Primary endpoints included HbA1c, mean sensor glucose, and percentages of time spent in predefined glycemic ranges. A total of 2,170 participants were included. AID therapy was associated with significant improvements in glycemic control. Time in the target range (70-180 mg/dL) and tight target range (70-140 mg/dL) increased, while mean sensor glucose and glucose variability decreased. Time below range (<70 mg/dL) was reduced. HbA1c improved without a significant change in total daily insulin dose. In this large multinational real-world cohort, AID therapy significantly improved glycemic outcomes and reduced hypoglycemia in children and adolescents with T1D. These findings support the effectiveness of AID systems across diverse clinical settings and underscore their value in pediatric diabetes care.